TOPLINE:
Treatment with Paxlovid in older adults did not appear to make a difference in whether or not they were hospitalized because of COVID-19.
METHODOLOGY:
- Over a 9-month time span starting in April 2022, researchers analyzed the hospital data of over 1.6 million Ontario residents aged 65 to 74 years.
- Nearly 88% of all patients had received at least two COVID-19 vaccines.
- The study followed Ontario’s age-restrictive policy, which reserved Paxlovid for adults aged ≥ 70 years with a positive COVID-19 test, unless they were immunocompromised or had fewer than three COVID-19 vaccinations plus another risk factor such as a diabetes diagnosis.
- Researchers compared outcomes of patients from ages 65 to 69 years and ages 70 to 74 years who were similar except for their exposure to Paxlovid.
TAKEAWAY:
- Nine months after an…